Summary: An attempt was made to achieve earlier detection of busulphan lung (fibrosing alveolitis) and to determine its incidence by means of serial studies during life, including measurement of the gas transfer factor. Twenty-three patients were investigated over an average period of nearly two years of busulphan treatment. One case of busulphan lung was detected and subsequently confirmed at necropsy, but in the remainder there was no clinical, radiological, or physiological evidence of fibrosing alveolitis. It is concluded that the development of fibrosing alveolitis may be related to individual genetic or immunological factors rather than to busulphan dosage.
Introduction
Busulphan is an alkylating agent introduced into clinical practice by Galton in 1953. It is the treatment of choice for chronic myeloid leukaemia and is also useful in the management of other myeloproliferative disorders such as polycythaemia rubra vera and mvelosclerosis.
Bone marrow depression is the principal hazard of busulphan therapy (Weatherall, Galton, and Kay, 1969) , but hyperpigmentation and amenorrhoea also occur (Kyle, Schwartz, Oliner, and Dameshek, 1961) . Though Oliner, Schwartz, Rubio, and Dameshek (1961) first recognized fibrosing alveolitis as a complication of prolonged busulphan therapy, only 10 clinical cases have been reported, and for most of these the total dose of busulphan and the detailed results of lung function tests were not recorded (Table I) . Despite these few clinical cases Heard and Cooke (1968) found histological changes attributed to busulphan in the lungs of 6 out of 14 cases (43%) of chronic myeloid leukaemia coming to necropsy. A diagnosis of pulmonary fibrosis had been made in only one of these patients during life. Heard's work suggested to us that more cases of busulphan lung might be diagnosed during life if careful observation of patients receiving the drug were maintained.
The purpose of the present report is to describe the results of serial clinical, radiological, and physiological studies in a group of patients treated with busulphan, with particular reference to the gas transfer factor. *Medical Registrar.
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Patients and Methods Twenty-three patients (12 males and 11 females) with an average age of 51 years (range 15-77) were studied. The haematological diagnoses included chronic myeloid leukaemia (17 cases), polycythaemia rubra vera (3 cases), myelosclerosis (2 cases), and thrombocythaemia (1 case).
The following investigations were carried out: (1) a clinical history and examination; (2) a chest radiograph; (3) the subdivisions of lung volume including vital capacity (VC), functional residual capacity (FRC), and residual volume (RV)-FRC and RV were measured by a closed-circuit helium technique; (4) maximum voluntary ventilation at 80 respirations per minute (MVV); (5) the forced expiratory volume in 1 second (FEV1); (6) arterial Pco2 by the rebreathing method; and (7) transfer factor for carbon monoxide (TLCO) by the single-breath technique. In 17 patients these investigations were carried out on two separate occasions, after an average of 14 and 21 months' treatment respectively.
The normal values for lung volumes were predicted from the formula of Baldwin, Cournand, and Richards (1948) . Normal values for the gas transfer factor were predicted from the formula of Ogilvie, Forster, Blakemore, and Morton (1957) .
Results
The clinical and radiological findings are presented in Table II and the results of the physiological tests in Tables  III and IV . For convenience of discussion the patients were divided into two groups. Group 1 comprised 17 showing no significant impairment of gas transfer factor. Twelve of these were studied on two separate occasions (Table V) . All 17 were symptom-free, and the chest radiograph was normal in every case. Group 2 comprised the following six patients showing a low transfer factor on one or more occasions:
Case 4 was the only patient in the whole series to develop "busulphan lung." His gas transfer factor was reduced to 25% of the predicted normal. He had received 1,000 mg. of busulphan over a period of 19 months. Full details of this case are reported elsewhere (Littler, Kay, Hasleton, and Heath, 1969).
Cases 11 and 21 had a low transfer factor on both occasions they were studied. These two men had severe chronic airways obstruction with an FEV1% of less than 50. Both were cigarette smokers and Case 21 had been a boiler scaler for 20 years. (Table  VI compares the mean gas transfer factor and FEV1% of these two patients with those in group 1.) Neither of these patients 
Discussion
Fibrosing alveolitis is a rare but serious complication of busulphan therapy. Measurement of the gas transfer factor is probably the most reliable method for the early detection of fibrosing alveolitis during life. In our 23 patients receiving busulphan the transfer factor was impaired (less than 70% of predicted normal) in six, and in one of these a diagnosis of busulphan lung was established at necropsy. Two patients (Cases 11 and 21) had a low transfer factor at both visits and each showed clinical and physiological signs of obstructive airways disease without radiological evidence of fibrosing alveolitis or any deterioration in transfer factor with continued busulphan treatment. In the remaining three patients (Cases 14, 16, and 18) the transfer factor had fallen into the abnormal range at the second visit, while a further three (Cases 7, 13, and 15) showed a significant fall in transfer factor to the lower limit of the normal range. In four of these six patients a commensurate fall in the haemoglobin level occurred between the first and second visits, and a fifth patient (Case 14) was anaemic on both occasions. In none of these patients was there any clinical, spirometric, or radiological evidence of fibrosing alveolitis. Bates and Christie (1964) drew attention to the fact that the transfer factor may be low in the presence of anaemia, and an appropriate correction formula for this is now being evolved by Cotes (personal communication, 1970) .
Two patients (Cases 6 and 10) had a transfer factor above 130°% of their predicted normal, and one of these was a young woman taking the oral contraceptive pill. [F. F. alveolitis due to "busulphan lung." The other four patients died after a myeloblastic crisis, and in two of these no histological abnormality of the lung was found at necropsy. In the other two cases permission for necropsy was refused, but antemortem chest radiographs and physiological studies were normal. Two of these patients had received a much larger dose of busulphan than the patient who developed fibrosing alveolitis (Table VII) , and a further six patients who are alive and well also received a dose in excess of 1,000 mg. (see Table II ). The lack of any relationship between busulphan dosage and transfer factor is illustrated in the Chart. Hence the development of fibrosing alveolitis may be related to the genetic or immunological constitution of the patient rather than to the dose or duration of busulphan therapy.
The preliminary results of this study suggest that lung damage, detectable during life, is a relatively uncommon complication of busulphan treatment, occurring in only 1 out of 23 patients closely studied over an average period of nearly two years.
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